October 4, 2016
Press release
Teikoku Seiyaku Co., Ltd.
Mitsubishi Tanabe Pharma Corporation

Execution of Basic Agreement for Sales
Anti-Allergy Agent, Rupatadine Tablets
Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa; President and CEO: MisakoFujioka) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka City; President andRepresentative Director: Masayuki Mitsuka) have reached a basic agreement for sales of Rupatadinetablets (generic name: rupatadine fumarate) in Japan.
Rupatadine tablets are an oral anti-allergy agent developed by J. Uriach Y COMPANIA, S.A., in Spain.
The drug is marketed in more than 60 countries around the world, mainly in Europe, principally underthe brand name Rupafin®. Overseas, it has indications of allergic rhinitis and urticaria and isadministered orally at a dosage of 10mg once a day.
In Japan, Teikoku Seiyaku is developing Rupatadine and plans to file an application for manufacturingand marketing approval shortly. After the approval is granted, Teikoku Seiyaku will supply finishedproducts to Mitsubishi Tanabe Pharma and Mitsubishi Tanabe Pharma will distribute and sell theproducts to the market. Medicinal drug promotion will be conducted jointly by both companies.
In addition, the two companies have reached an agreement regarding co-promotion activities forTalion® tablets. According to the agreement, Teikoku Seiyaku is going to start co-promotion of Talion®
tablets from January 1, 2017. Through these activities, Teikoku Seiyaku and Mitsubishi Tanabe
Pharma aim to implement the medicinal drug promotion more promptly after the launch of Rupatadinetablets and to propose two treatment options — Rupatadine tablets and Talion® tablets — to patients inaccordance with their symptoms and lifestyles.
Kiyoshi Ohta, Executive Director, Sales & Marketing Department at Teikoku Seiyaku, said “Teikoku
Seiyaku has been working to broadly address the needs of patients by developing drugs from thepatient’s viewpoint and providing the drugs to the market in collaboration with sales partners thatspecialize in the therapeutic areas of those drugs. We believe the agreements will enable us to deliver
Rupatadine tablets, the newest anti-allergy agent in Japan, to more patients through close cooperative
relationship with Mitsubishi Tanabe Pharma, which has a strong presence in the field of allergicdisorders.
Yoshiaki Ishizaki, Director, Managing Executive Officer, and Division Manager of Sales & Marketing
Division for Mitsubishi Tanabe Pharma, said “As with the priority disease areas under ourMedium-Term Management Plan, we will continue to advance strategic sales and marketing activities
in the field of allergic disorders. Under this agreement, Mitsubishi Tanabe Pharma and Teikoku
Seiyaku will work together to provide information regarding Talion® to a larger number of medicalinstitutions. Furthermore, following the acquisition of manufacturing and marketing approval for
Rupatadine tablets, we will be able to offer a new treatment option. Through these two drugs, we will
be able to make a further contribution to the treatment of allergic disorders.”About Teikoku Seiyaku

Teikoku Seiyaku is a privately-owned specialty pharmaceutical company headquartered in Kagawa,Japan. Based on the years of experience in development of anti-inflammatory/analgesic patch
technology, Teikoku has been specializing in “analgesic” and “transdermal” medications. In 2014,
Teikoku established its own sales force and began marketing not only patch products, but oral andtopical drugs to address the patient’s needs in the field of dermatology and pain. Teikoku’s goal is toimprove the quality of life of people through developing and providing novel and unique drugs in thefields.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company with a Head Officebased in Dosho-machi Osaka, the birthplace of Japan’s pharmaceutical industry. As part of its“Medium-Term Management Plan 16-20: Open Up the Future,” the company is focused on discoveringdrugs that address unmet medical needs in several priority disease areas, including central nervous systemdiseases, autoimmune disorders, diabetes, kidney disease and vaccines. Through this work, the company
contributes to the healthier lives of people around the world. For more information, go to
www.mt-pharma.co.jp/e.
For further information, please contact:
Teikoku Seiyaku Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
General Affairs Department
Corporate Communications Department
TEL：+81-6-6205-5211

TEL：+81-879 -25-2221